Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Asset Writedowns and Impairment (2019 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Asset Writedowns and Impairment for 9 consecutive years, with $828000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 169.71% to $828000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 69.42% increase, with the full-year FY2024 number at $485000.0, up 35.85% from a year prior.
  • Asset Writedowns and Impairment was $828000.0 for Q3 2025 at Xtant Medical Holdings, up from -$51000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $828000.0 in Q3 2025 to a low of -$210000.0 in Q4 2024.
  • A 5-year average of $235684.2 and a median of $155000.0 in 2023 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 2327.27% in 2021, then tumbled 412.2% in 2024.
  • Xtant Medical Holdings' Asset Writedowns and Impairment stood at $267000.0 in 2021, then fell by 8.61% to $244000.0 in 2022, then crashed by 116.8% to -$41000.0 in 2023, then crashed by 412.2% to -$210000.0 in 2024, then skyrocketed by 494.29% to $828000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Asset Writedowns and Impairment are $828000.0 (Q3 2025), -$51000.0 (Q2 2025), and $541000.0 (Q1 2025).